Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neuropeptides Exert Neuroprotective Effects in Alzheimer's Disease
Xinyi Chen, Yifeng Du, Lei Chen
Frontiers in Molecular Neuroscience (2019) Vol. 11
Open Access | Times Cited: 99

Showing 1-25 of 99 citing articles:

Probiotics for Alzheimer’s Disease: A Systematic Review
Ruth Naomi, Hashim Embong, Fezah Othman, et al.
Nutrients (2021) Vol. 14, Iss. 1, pp. 20-20
Open Access | Times Cited: 108
Roles of Neuropeptide Y in Neurodegenerative and Neuroimmune Diseases
Chunrong Li, Xiujuan Wu, Shan Liu, et al.
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 86
Relationships Between Neurodegeneration and Vascular Damage in Diabetic Retinopathy
Maria Grazia Rossino, Massimo Dal Monte, G. Casini
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 81
Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease
Steven N. Austad, Scott W. Ballinger, Thomas W. Buford, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 2, pp. 511-531
Open Access | Times Cited: 56
Exploring the Therapeutic Effect of Neurotrophins and Neuropeptides in Neurodegenerative Diseases: at a Glance
Md. Mominur Rahman, Md. Rezaul Islam, Fatema Akter Supti, et al.
Molecular Neurobiology (2023) Vol. 60, Iss. 8, pp. 4206-4231
Closed Access | Times Cited: 22
Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective
Naif H. Ali, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 28, Iss. 2
Open Access | Times Cited: 22
Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases
Xin Yi Yeo, Grace Cunliffe, Roger Ho, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 343-343
Open Access | Times Cited: 33
Probiotics and the microbiota-gut-brain axis in neurodegeneration: Beneficial effects and mechanistic insights
Fatemeh Taghizadeh Ghassab, Fatemeh Shamlou Mahmoudi, Reyhaneh Taheri Tinjani, et al.
Life Sciences (2024) Vol. 350, pp. 122748-122748
Closed Access | Times Cited: 7
Neuropeptides in Alzheimer’s Disease: An Update
Carla Petrella, Maria Grazia Di Certo, Christian Barbato, et al.
Current Alzheimer Research (2019) Vol. 16, Iss. 6, pp. 544-558
Closed Access | Times Cited: 45
Neuromedin U signaling regulates retrieval of learned salt avoidance in a C. elegans gustatory circuit
Jan Watteyne, Katleen Peymen, Petrus Van der Auwera, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 39
The Emerging Role of Neuropeptides in Parkinson’s Disease
Yanan Zheng, Linlin Zhang, Junxia Xie, et al.
Frontiers in Aging Neuroscience (2021) Vol. 13
Open Access | Times Cited: 39
Polyamine Dysregulation and Nucleolar Disruption in Alzheimer’s Disease
Wesley Harrell Brooks
Journal of Alzheimer s Disease (2024) Vol. 98, Iss. 3, pp. 837-857
Open Access | Times Cited: 4
Neuropathology-based approach reveals novel Alzheimer's Disease genes and highlights female-specific pathways and causal links to disrupted lipid metabolism: insights into a vicious cycle
Yin Hua Jin, Apostolia Topaloudi, Sudhanshu Shekhar, et al.
Acta Neuropathologica Communications (2025) Vol. 13, Iss. 1
Open Access
Mechanisms of comorbidity between Alzheimer's disease and pain
Kaifang Yao, Shenjun Wang, Zhifang Xu, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access
Neuroprotective Peptides in Retinal Disease
Davide Cervia, Elisabetta Catalani, G. Casini
Journal of Clinical Medicine (2019) Vol. 8, Iss. 8, pp. 1146-1146
Open Access | Times Cited: 31
Alterations in pituitary adenylate cyclase-activating polypeptide in major depressive disorder, bipolar disorder, and comorbid depression in Alzheimer's disease in the human hypothalamus and prefrontal cortex
Zala Slabe, Rawien Balesar, R.W.H. Verwer, et al.
Psychological Medicine (2023) Vol. 53, Iss. 16, pp. 7537-7549
Open Access | Times Cited: 10
EndoGenius: Optimized Neuropeptide Identification from Mass Spectrometry Datasets
Lauren Fields, Nhu Q. Vu, Tina C. Dang, et al.
Journal of Proteome Research (2024) Vol. 23, Iss. 8, pp. 3041-3051
Open Access | Times Cited: 3
Anorexigenic neuropeptides as anti-obesity and neuroprotective agents
Veronika Strnadová, Andrea Pačesová, Vilém Charvát, et al.
Bioscience Reports (2024) Vol. 44, Iss. 4
Open Access | Times Cited: 3
Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future
Salvatore Corrao, Luigi Calvo, Walter Granà, et al.
Nutrition Metabolism and Cardiovascular Diseases (2024) Vol. 35, Iss. 2, pp. 103702-103702
Closed Access | Times Cited: 3
Anxiolytic impact of Apelin-13 in a rat model of Alzheimer's disease: Involvement of glucocorticoid receptor and FKBP5
Samaneh Aminyavari, Maryam Zahmatkesh, Fariba Khodagholi, et al.
Peptides (2019) Vol. 118, pp. 170102-170102
Closed Access | Times Cited: 27
Current Strategies and Novel Drug Approaches for Alzheimer Disease
Roma Ghai, Kandasamy Nagarajan, Meenakshi Arora, et al.
CNS & Neurological Disorders - Drug Targets (2020) Vol. 19, Iss. 9, pp. 676-690
Closed Access | Times Cited: 25
Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
Qi Cheng, Jinluo Cheng, Dennis Cordato, et al.
Pharmacology & Therapeutics (2020) Vol. 212, pp. 107559-107559
Closed Access | Times Cited: 22
A Review on the Protective Effects of Probiotics against Alzheimer’s Disease
Vibhuti Mishra, Dhananjay Yadav, Kavita Singh Solanki, et al.
Biology (2023) Vol. 13, Iss. 1, pp. 8-8
Open Access | Times Cited: 7
Research progress on the protection and mechanism of active peptides in Alzheimer's disease and Parkinson's disease
Xuying Ding, Yutong Chen, Xiaojun Zhang, et al.
Neuropeptides (2024) Vol. 107, pp. 102457-102457
Closed Access | Times Cited: 2
The angiotensin (1–7) glycopeptide PNA5 improvescognition in achronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation
Kelsey Bernard, J A Mota, Paige V Wene, et al.
Experimental Neurology (2024) Vol. 381, pp. 114926-114926
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top